Objective. To elucidate the role of the fractalkine (FKN)/CX 3 CR1 pathway in joint destruction in rheumatoid arthritis. Methods. We examined the effect of treatment with anti-mouse FKN (anti-mFKN) monoclonal antibody (mAb) on joint destruction and the migration of osteoclast precursors (OCPs) into the joint, using the collagen-induced arthritis (CIA) model. DBA/1 mice were immunized with bovine type II collagen to induce arthritis, and then treated with anti-mFKN mAb. Disease severity was monitored by arthritis score, and joint destruction was evaluated by soft x-ray and histologic analyses. Plasma levels of joint destruction markers were assessed by enzyme-linked immunosorbent assay. FKN expression on endothelial cells was detected by immunohistochemistry. Bone marrow-derived OCPs were labeled with fluorescein and transferred to mice with CIA, and the migration of the OCPs to the joints was then analyzed.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic autoimmune disease that is characterized by synovitis, progressive bone erosion, and cartilage destruction. A hallmark of RA is the rapid recruitment of leukocytes to the site of inflammation. Additionally, patients with active RA exhibit elevated levels of activated peripheral leukocytes, especially monocyte/macrophages, which may contribute to the immunopathogenesis of RA (1) . In addition, RA is exacerbated and perpetuated by proinflammatory cytokines, including tumor necrosis factor (TNF) and interleukin-6 (IL-6), which are produced primarily by monocyte/macro phages and play a critical role in the pathogenesis of joint inflammation and destruction (2, 3) . Several biologic agents are widely used to relieve RA symptoms, and notable examples of these include anti-TNF agents. However, up to 30% of RA patients either do not respond to existing medications or must discontinue treatment, typically because of adverse effects or limited drug efficacy (4) . Moreover, systemic suppression of TNF may be associated with the development of serious infections (5) .
Chemokines and their receptors orchestrate tissue-specific and cell type-selective trafficking and retention of leukocytes (6) .
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Elevated levels of several chemokines have been detected in the synovial tissue and synovial fluid of RA patients (7) . CX 3 CL1/fractalkine (FKN) is a membrane-bound chemokine with a chemokine/mucin hybrid structure and a transmembrane domain (8) . The unique structure of FKN allows it to work as an adhesion molecule when it is in the membrane-bound form, and as a chemoattractant when it is in the soluble form; transformation into the soluble form follows cleavage of FKN by ADAM-10 or ADAM-17 (9) . FKN promotes extravasation of circulating leukocytes by binding to its receptor, CX 3 CR1, through integrinindependent and -dependent mechanisms (10) . Synovial fluid and serum FKN concentrations are increased in patients with RA, compared with osteoarthritis patients and healthy controls. In addition, serum FKN concentration correlates with disease severity in patients with RA (11) .
Increased expression of FKN is exhibited in activated endothelial cells and fibroblasts in patients with RA, as well as in rat models of arthritis (12, 13) . CX 3 CR1 is expressed on monocyte/macrophages, osteoclast precursors (OCPs), cultured RA fibroblast-like synoviocytes (FLS), effector CD4+ T cells and killer CD8+ T cells, and dendritic cells (DCs) (12) (13) (14) (15) . Multinucleated giant osteoclasts are bone-resorbing cells that differentiate from OCPs, which differentiate from the monocyte/macrophage lineage that is derived from bone marrow cells (16) . RANKL, which is derived from osteoblasts and activated synovial fibroblasts, binds to RANK, its specific membrane-bound receptor, on OCPs/pre-osteoclasts, whereby OCPs/pre-osteoclasts begin differentiation into osteoclasts (17) . FKN induces the migration of OCPs and monocyte/macrophages expressing CX 3 CR1 positivity, as well as the differentiation of osteoclasts in vitro (15, 18) . Therefore, the interaction between FKN and CX 3 CR1 may play an important role in inflammation due to monocyte/macrophage infiltration and in the regulation of OCPs and their differentiation to osteoclasts. In a previous study, an anti-FKN-neutralizing monoclonal antibody (mAb) reduced the migration of inflammatory cells into the synovium in a bovine type II collageninduced arthritis (CIA) mouse model in vivo (14) . However, the precise mechanisms of the FKN/CX 3 CR1 pathway in the pathology of RA, especially those of bone and cartilage destruction, have not yet been elucidated. In the present study, we investigated the role of the FKN/CX 3 CR1 pathway in a mouse model of CIA using an anti-mouse FKN (anti-mFKN) mAb, with emphasis on the mechanism of joint destruction.
MATERIALS AND METHODS
Animals. All animal studies were approved by the Animal Ethics Committee at Eisai Company/KAN Research Institute and conducted in accordance with their Laboratory Animal Welfare guidelines. Male DBA/1 mice (5-6 weeks old) were obtained from Charles River Japan. Mice were reared within a Japan Health Sciences Foundation-accredited animal facility, and they were group-housed under controlled conditions with a constant temperature (23°C [± 3°C]) and humidity (55% [± 5%]), on a 12-hour light/dark cycle, with ad libitum access to water and standard pelleted food.
Antibodies and reagents. Monoclonal antibody against mFKN was generated from Armenian hamsters that were immunized with recombinant mFKN (R&D Systems) using a standard method at KAN Research Institute. The clone 5H8-4 was selected as an anti-mFKN-neutralizing mAb that was highly specific to mFKN, as determined by enzyme-linked immunosorbent assay (ELISA) with a panel of mouse chemokines, and by chemotaxis assay using mouse CX 3 CR1 (mCX 3 CR1)-expressing cells (14) . Hamster IgG (used as a control) was generated from Armenian hamsters immunized with dinitrophenol (DNP). For flow cytometry, the clone L2D11 was selected as an anti-mCX 3 CR1 mAb that was highly specific to mCX 3 CR1 (Nishimura M, et al, unpublished observations). An isotype-matched control IgG was purchased from Jackson ImmunoResearch. For flow cytometry and immunohistochemical analysis, the following antibodies were used: Alexa Fluor 488-conjugated rat anti-mouse CD115 mAb (AFS98; BioLegend), allophycocyanin-Cy7-conjugated rat anti-mouse CD11b mAb (M1/70; eBioscience), rat anti-mouse RANK mAb (LOB14-8; Bio-Rad), goat anti-mFKN poly clonal antibody (pAb) (R&D Systems), rat anti-mouse CD31 mAb (390; BioLegend), and goat anti-cathepsin K pAb (Santa Cruz Bio technology).
An Alexa Fluor 647 protein labeling kit was purchased from ThermoFisher Scientific for the labeling of goat anti-cathepsin K pAb. A Phycolink R-Phycoerythrin conjugation kit was purchased from ProZyme for the labeling of the anti-mCX 3 CR1 mAb. To detect primary antibodies, secondary antibodies from Jackson ImmunoResearch were used. A mouse CD115 MicroBead kit was purchased from Miltenyi Biotec. A CellTrace 5,6-carboxyfluorescein succinimidyl ester (CFSE) cell proliferation kit (ThermoFisher Scientific) was used for cell labeling. For cell cultures, recombinant mouse macrophage colonystimulating factor (M-CSF) and RANKL were purchased from R&D Systems; RPMI 1640 medium (ThermoFisher Scientific), fetal bovine serum (FBS; Nichirei Biosciences), 2-mercaptoethanol (2-ME), and sodium pyruvate (both from ThermoFisher Scientific) were also used for cell culture protocols.
Induction and assessment of CIA. Bovine type II collagen (Collagen Research Center) was dissolved in 0.05M acetic acid (3 mg/ml) and emulsified in an equal volume of Freund's complete adjuvant (Difco). Mice were immunized intracutaneously with 100 μl of the emulsion at the base of the tail. On day 21 postimmunization, the mice were boosted with the same amount of bovine type II collagen, emulsified in Freund's incomplete adjuvant (Difco). The progression of arthritis was monitored continuously after the first immunization by assessing the arthritis score (defined as the sum of scores on a scale of 0-4 for all 4 limbs and based on the swelling of the limbs, for a total possible score of 16 for each mouse), using methods modified from those of Seeuws et al (19) and Huang et al (20) . The arthritis score measured disease severity as follows: 0 = a normal joint, without inflammation or redness; 1 = redness and swelling in 1 digit; 2 = redness and swelling in 2 digits, or redness and mild swelling in the ankle and wrist joints; 3 = redness and swelling in >3 digits, or moderate swelling in the ankle and wrist joints and the paw; and 4 = severe swelling in the ankle and wrist joints and the paw. The arthritis score for each mouse was defined as the sum of the scores of all 4 feet.
Antibody treatment.
In the prophylactic treatment study, 400 μg of hamster anti-mFKN mAb (clone 5H8-4) or control IgG (anti-DNP mAb) was administered intraperitoneally to 8-12 mice twice per week from the day of the first immunization. In the therapeutic treatment study, when the arthritis score had reached 1-3 (early arthritis) or 6-8 (severe arthritis), mice were randomly assigned to receive anti-mFKN mAb or control IgG (400 μg/ mouse, 4-9 mice/group) intraperitoneally twice weekly.
Soft x-ray analysis.
At the end point, mice were killed, and radiologic analysis of all 4 limbs was performed to determine the soft x-ray score for bones of the limb (scale 0-36 per mouse), which is the sum of 3 parameters (osteopenia, bone erosion, and new bone formation) on a scale of 0-3. This analysis was performed for all 4 limbs in a blinded manner using methods modified from a study by Inoue et al (21) .
Measurement of plasma parameters. Plasma levels of cartilage oligomeric matrix protein (COMP; AnaMar AB) and matrix metalloproteinase 3 (MMP-3; R&D Systems) were assessed by ELISA, according to the instructions of the manufacturers.
Histologic analysis.
At the end point of the animal study, mice were deeply anesthetized with isoflurane and perfused with phosphate buffered saline (PBS) and 1% paraformaldehyde in PBS. After perfusion, all 4 limbs were collected from each mouse and postfixed with 1% paraformaldehyde in PBS at 4°C for 24 hours. After the limbs were postfixed, they were washed with PBS and placed in 0.5M EDTA (Invitrogen) for 5 days to decalcify. The skin, muscles, and ligaments were peeled off the limbs, and the limb samples were cryoprotected in 10% and 20% sucrose in PBS, then embedded in Tissue-Tek OCT compound (Sakura Finetek). Cryosections were obtained by cutting OCT blocks of 10-μm thickness, using the method described by Kawamoto and Kawamoto (22) (type C9 film; Leica Microsystems). Frozen sections of the limb samples were then examined histologically. Samples were stained with 1 of the following: hematoxylin and eosin (H&E) solution; acid phosphatase, leukocyte (tartrateresistant acid phosphatase [TRAP]) kit (Sigma-Aldrich); or Alcian blue (AB)/alizarin red (AR). Using a BioRevo BZ-X710 microscope (Keyence), a constant view area of the joint, centered on the bone marrow cavity, was taken with a low-power field (10×, 20×). The number of TRAP+ cells per field was counted. TRAP+ cells were analyzed with NIS-Elements image analysis software (Nikon) in a blinded manner, using methods modified from those of Ono et al (23) . The number of TRAP+ osteoclasts was averaged for all the joints in 1 limb of each animal. To evaluate cartilage and bone destruction, AB/AR staining was performed. The sections were incubated in 1% AB (AB staining kit, pH 2.5) (ScyTek). After the sections were rinsed with distilled water, they were incubated in 0.1% AR, pH 6.0 (Wako).
Histologic scoring. Histologic scores were obtained using H&E-stained sections (low-power field, 10×) and AB/ AR-stained sections (low-power field, 20×) via NIS-Elements image analysis software. For histologic analysis of arthritis severity, scoring was performed in a blinded manner based on a previously described method (24) . Sections were scored according to changes in synovitis (where 0 = no changes, 1 = >2 cell layers, 2 = >5 cell layers, and 3 = >5 cell layers, combined with pannus formation), changes in cartilage damage (where 0 = no changes, 1 = erosion in part of the cartilage surface, 2 = erosion of the cartilage surface and cartilage destruction, and 3 = cartilage erosion and destruction, combined with cartilage covered by connective tissue), and changes in bone destruction (where 0 = no changes, 1 = bone remodeling close to the joint capsule, 2 = bone remodeling in deeper locations, reaching the epiphyseal plate, and 3 = deep bone remodeling and bone degradation). In each category, joints were independently evaluated in a blinded manner. The synovitis score, cartilage score, and bone destruction score were averaged for all the joints in 1 limb of each animal.
Immunohistochemistry. For immunohistochemical analysis, sections were washed twice with 0.1% Triton X-100 in PBS and blocked in Block Ace (DS Pharma Biomedical) at room temperature for 1 hour. They were then incubated with primary antibodies at room temperature for 2 hours, followed by 3 washes with 0.1% Triton X-100 in PBS and incubation with the following secondary antibodies: fluorescein-or Cy3-conjugated anti-rabbit or anti-mouse IgG (Jackson ImmunoResearch). Sections were then incubated at room temperature for 1 hour, washed 3 times with 0.1% Triton X-100 in PBS, and mounted with Prolong Gold mounting medium (ThermoFisher Scientific). The prepared sections were analyzed by confocal laser microscopy (Nikon A1).
Preparation and characterization of OCPs for adoptive transfer. Bone marrow from normal DBA/1 mice was cultured in RPMI 1640 medium, containing 50 ng/ml M-CSF, 10% FBS, sodium pyruvate, and 2-ME for 2 days (25). CD11b, CD115, RANK, and | 225 CX 3 CR1 expression levels on adherent cells were analyzed by flow cytometry, based on a previously described method (26) . Adherent cells were purified using a CD115 MicroBead Kit (Miltenyi Biotec). A CellTrace CFSE cell proliferation kit (10 μM; ThermoFisher Scientific) was used to label CD115+ cells according to the instructions of the manufacturer, thereby generating CFSE-labeled cells. These CFSE-labeled cells were cultured in RPMI 1640 medium containing 10 ng/ml M-CSF, 25 ng/ml RANKL, 10% FBS, sodium pyruvate, and 2-ME for 5-6 days; the cells were then stained using an acid phosphatase, leukocyte (TRAP) kit.
Analysis of the migration of adoptively transferred
OCPs into the synovium in mice with CIA. Recipient mice with CIA were injected intraperitoneally with 400 μg of anti-mFKN mAb or control IgG 24 hours and 2 hours before cell transfer. CFSElabeled OCPs (5 × 10 5 ) were injected intravenously into the mice. One hour or 24 hours after cell transfer, the limbs of the mice were collected. The number of CFSE+ cells in the synovium, or the positive area of CFSE+ cells in the cathepsin K+ area within the joint, was quantified with NIS-Elements image analysis software, and the number of CFSE+ cells and the ratio (CFSE+ area to cathepsin K+ area) were calculated, based on a modification of a previously described method (27) . A total of 7-8 slides from each mouse (n = 7-8 mice) were independently evaluated in a blinded manner.
Statistical analysis. Data were expressed as the mean ± SEM. For statistical analysis, the nonparametric Kruskal-Wallis test was performed, followed by the Mann-Whitney U test. P values less than 0.05 were considered significant. Statistical analyses were performed using GraphPad Prism software, version 6.02 (see Supplementary Materials and Methods, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/ doi/10.1002/art.40688/abstract).
RESULTS
Effects of prophylactic treatment with anti-mFKN mAb. Prophylactic treatment with anti-mFKN mAb significantly suppressed the progression of CIA, as demonstrated by decreases in the arthritis score and as compared with the joints of mice treated with control IgG (Figures 1A and E) . Administration of anti-mFKN mAb significantly reduced bone destruction compared with control IgG, as determined by soft x-ray analysis ( Figure 1B ). Plasma levels of COMP, a marker of cartilage destruction, and MMP-3, a marker that reflects synovitis and cartilage destruction, were also significantly reduced in the anti-mFKN mAb-treated group compared with the control IgGtreated group (Figures 1C and D) . At the joint, gene expression levels of TNF and IL-6, markers that reflect local inflammation, were significantly reduced in the anti-mFKN mAb-treated group compared with the control IgG-treated group (see Supplementary Figure 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/ art.40688/abstract).
To more accurately evaluate the extent of joint destruction, pathologic analyses were performed. Histologic analysis by H&E staining revealed that synovitis and pannus formation, which were not seen in the normal mice, were present in control IgG-treated mice ( Figure 1F ). Conversely, these same symptoms were suppressed in anti-mFKN mAb-treated mice. Cartilage was also degraded in control IgG-treated mice compared with normal mice; however, mice that were treated with the anti-mFKN mAb retained cartilage and rarely exhibited destruction ( Figure 1G ). Furthermore, TRAP+ osteoclasts were rarely detected in the joints of normal mice, whereas a large number of TRAP+ osteoclasts were detected in the joints of control IgG-treated mice ( Figure 1H ). In contrast, TRAP+ osteoclasts were rarely detected in the joints of anti-mFKN mAb-treated mice.
Effects of therapeutic treatment with anti-mFKN mAb.
To mimic therapeutic intervention in human patients with RA, anti-mFKN mAb was administered after the onset of arthritis. Therapeutic treatment with anti-mFKN mAb significantly decreased the arthritis score ( Figure 2A) and soft x-ray score (Figure 2B ) compared with treatment with control IgG. In affected joints, histologic analysis revealed that synovitis and pannus formation were inhibited in anti-mFKN mAb-treated mice compared with control IgG-treated mice ( Figure 2C ). Cartilage was also degraded in control IgG-treated mice compared with normal mice; however, mice that were treated with anti-mFKN mAb retained cartilage and rarely exhibited destruction ( Figure 2D ). TRAP+ osteoclasts were scarce in the joints of normal mice, whereas a large number of TRAP+ osteoclasts were detected in the joints of control IgG-treated mice. In contrast, TRAP+ osteoclasts were rarely detected in the joints of anti-mFKN mAb-treated mice (Figure 2E) . Furthermore, synovitis, cartilage, and bone destruction scores were all significantly reduced in the anti-mFKN mAbtreated group compared with the control IgG-treated group (Figures 2F-H) . Quantitative analysis showed that the reduction in the number of TRAP+ osteoclasts in the joints of mice in the antimFKN mAb-treated group compared with mice in the control IgG-treated group was statistically significant ( Figure 2I ). 
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We next examined the effect of therapeutic treatment with anti-mFKN mAb on severe CIA. Anti-mFKN mAb did not decrease the arthritis score ( Figure 3A) . However, histologic analysis revealed that synovitis, cartilage destruction, and bone damage were clearly inhibited in anti-mFKN mAb-treated mice compared with control IgG-treated mice (Figures 3B-D) . Additionally, the synovitis, cartilage, and bone destruction scores all decreased significantly in the anti-mFKN mAb-treated group compared with the control IgG-treated group (Figures 3E-G) , and the number of TRAP+ osteoclasts was significantly reduced in the joints of mice in the anti-mFKN mAb-treated group compared with joints of mice in the control IgG-treated group ( Figure 3H ). Taken together, these results indicate that anti-mFKN mAb suppressed the destruction of the affected joints, irrespective of edema as evaluated by the arthritis score.
Effects of anti-mFKN mAb on OCP migration into the synovium of mice with CIA. Although FKN was scarcely detected on synovial vascular endothelial cells in normal mice ( Figures 4A and B) , it was expressed on a portion of synovial vascular endothelial cells in mice with CIA ( Figures 4C and  D) . Bone marrow-derived cells were cultured with M-CSF, and flow cytometry revealed that these CD11b high CD115+ cells coexpressed RANK and CX 3 CR1 ( Figure 5A ). Furthermore, after being purified with anti-CD115 mAb, CD115+ cells differentiated into TRAP+ multinucleated osteoclasts when cultured with M-CSF and RANKL in vitro ( Figure 5B ). Thus, we confirmed that bone marrow-derived CD11b high CD115+RANK+CX 3 CR1+ cells exhibit characteristics of OCPs. CFSE-labeled OCPs migrated into the synovium of control IgG-treated mice after 1 hour of transfer. In contrast, migration of these cells was strongly inhibited in anti-mFKN mAb-treated mice ( Figures 5C and E) . In addition, 24 hours after CFSE-labeled OCPs were transferred to control IgG-treated mice with CIA, these cells were positive for cathepsin K and became multinuclear osteoclasts in the joints. Conversely, cathepsin K+CFSE+ osteoclasts were rarely observed in joints of mice with CIA that were treated with anti-mFKN mAb ( Figures 5D and F and Supplementary Figure 2 , available on the Arthritis & Rheumatology web site at http://onlinelibrary. wiley.com/doi/10.1002/art.40688/abstract). In order to rule out other potential pathways involved in this mechanism of action, we tested whether OCPs derived from CX 3 CR1-knockout (KO) mice migrate into the synovium. We found reduced migration of CX 3 CR1-KO mice-derived OCPs into the synovium, compared with OCPs derived from wild-type mice (Supplementary Figure 3, http://onlinelibrary.wiley.com/doi/10.1002/art.40688/abstract). 
DISCUSSION
In the present study, we showed that anti-mFKN mAb suppressed the migration of OCPs into the affected synovium and decreased the number of mature osteoclasts, leading to the inhibition of bone destruction. Furthermore, anti-FKN mAb also inhibited synovitis and cartilage destruction. These results indicate that the FKN/CX 3 CR1 pathway plays a critical role in joint destruction via regulating the migration of OCPs.
OCPs express CX 3 CR1 and initially emerge in the synovium, where they differentiate into osteoclasts at an early stage of disease in the arthritic rat model (28) . In the present study, FKN was detected on a portion of synovial vascular endothelial cells in the affected synovium of mice with CIA; however, it was rarely detected on the synovial vascular endothelial cells of normal mice, suggesting that FKN+ vessels might serve as the migration gateway for OCPs to access the synovium in CIA pathology. Therefore, we examined whether anti-mFKN mAb could inhibit the migration of OCPs into the synovium. Transferred OCPs were detected in the vicinity of the FKN-expressing blood vessel in the synovium (results not shown). Importantly, the number of migrated OCPs was clearly reduced upon administration of antimFKN mAb, and a similar result was obtained when using OCPs of CX 3 CR1-KO mice. In mice with CIA that were treated with anti-mFKN mAb, the number of OCPs that differentiated into cathepsin K+ multinuclear osteoblasts was also reduced. These results suggest that the inhibition of progressive bone destruction by anti-mFKN mAb was, at least partially, because of the inhibition of OCP migration into the synovium and the resulting reduction in the number of osteoclasts. 
| 229
Anti-mFKN mAb has been shown to inhibit differentiation of bone marrow-derived OCPs into osteoclasts during coculture with osteoblasts (15). Hoshino et al reported that the FKN/ CX 3 CR1 pathway contributes to the maintenance of OCPs (26) . Moreover, FKN provides essential survival signals to CX 3 CR1-expressing monocytes, via activation of phosphatidylinositol 3-kinase (29) . Therefore, the interaction of FKN and CX 3 CR1 may also be involved in the differentiation of OCPs into osteoclasts, as well as in osteoclast survival after migration to the joints in mice with CIA. Furthermore, DCs have been reported to transdifferentiate into highly activated osteoclasts in inflammatory disorders such as RA (30) . Myeloid DCs express CX 3 CR1; thus, the role of these DC-derived osteoclasts in rheumatic disease and the expression of CX 3 CR1 in osteoclasts are topics of great interest.
Prophylactic treatment with anti-mFKN mAb has been shown to inhibit the onset and progression of CIA (14) , and migration of splenic F4/80+ macrophages into the synovium through the FKN/CX 3 CR1 pathway has been demonstrated to play a crucial role in arthritis initiation (31) . Synovium-infiltrating macrophages produce inflammatory cytokines and chemokines, thereby inducing the migration of immune cells; the combination of these factors results in the development of synovitis (32, 33) . FLS comprise hyperplastic synovial pannus and actively invade cartilage and bone in RA. Stimulation of FLS by synovial fibroblast-derived FKN or inflammatory cytokines from infiltrating macrophages up-regulates the production of MMP, an important enzyme that contributes to matrix degradation (12, 34) . Therefore, as a driving force that initiates autoimmunity and inflammation, FLS have been recognized to play a central role in joint destruction in RA (12) . In this study, anti-mFKN mAb also inhibited gene expression of inflammatory cytokines in joints and suppressed synovitis and pannus formation. Furthermore, anti-mFKN mAb inhibited COMP and MMP-3 production, as well as suppressed cartilage damage. Therefore, anti-mFKN mAb might also suppress cartilage destruction by reducing synovitis.
Although biologics are widely used to treat RA, some patients exhibit increased risk of complications (typically, severe infections) because of systemic administration (5, 35) . Several chemokine inhibitors have previously undergone clinical trials in RA patients; however, 2 inhibitors (SCH351125 and AZD5672), which target CCR5 expression on Th1 cells, did not suppress arthritis (36, 37) . Although CCL2 and CCR2 are representative chemokines involved in the migration of monocyte/macro phages, no improvement in arthritis symptoms was observed in a clinical trial using the anti-CCL2 antibody (ABN 912 and MLN1202) (38, 39) . Presumably, these insufficiencies in efficacy occurred because of ligand receptor redundancy and/or compensation by other chemokines that may bind to CCR2 and CCR5 (40) . In contrast, FKN is the sole high-affinity ligand for CX 3 CR1; therefore, redundancy may be absent from the FKN/CX 3 CR1 interaction.
Joint repair and erosion healing are suspected to be rare phenomena, despite effective treatment with TNF inhibitors (41) . Moreover, because some patients do not respond to anticytokine therapy, RA treatment requires control of cartilage and bone destruction by novel approaches (4). Treatments with humanized anti-FKN mAb (E6011) have been investigated in a clinical trial in RA patients (NCT02196558); these therapies were safe and well-tolerated in patients with inadequate responses to methotrexate or to TNF inhibitors (42) . In a clinical trial of RA treatment with humanized anti-FKN mAb (E6011), no serious adverse events (AEs) or deaths occurred; furthermore, no significant difference was observed in the incidence or severity of dose-dependent AEs (42) . Therefore, FKN/ CX 3 CR1 pathway inhibition, by a humanized anti-FKN mAb (E6011), may be a safe and attractive strategy to treat both inflammatory synovitis and joint destruction in RA. Furthermore, FKN and/or CX 3 CR1 exhibit increased expression in several inflammatory diseases, including atherosclerotic lesions (43) , severe acute hepatitis (44) , atopic dermatitis (45), asthma (46) , and systemic sclerosis (47) . Therefore, the FKN/CX 3 CR1 pathway may contribute to the pathogenesis of additional chronic inflammatory diseases, providing an attractive therapeutic target for modulation of local inflammatory cell accumulation.
